This Biotech’s Blockchain Partnership Could Transform Stem Cell Investing

A blockchain twist on stem cells. Investors are rushing to see if this bold tokenization play could rewrite the rules of medical investing.

Palantir is one of the most important AI companies in the world.

They don’t just work with anyone.

This is the same firm that powers the U.S. military’s battlefield intel and partners with top government agencies across the globe.

And now they’ve locked arms with a rising player in the autonomous robotics sector.

Together, they’re fusing real-time surveillance with predictive AI.

That means faster response times, smarter security, and a new era of automation.

One side brings millions of hours of operational security data.

The other brings some of the most powerful AI software on Earth.

The market hasn't caught up to this yet.  But when it does, you don’t want to be late.

Because this isn't a science project.

This is revenue-generating tech already deployed in corporate campuses, hospitals, and government buildings across the country.

Now with this AI partnership, the real ramp-up begins.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

U.S. stocks were mixed on Wednesday as Nvidia led a broad tech selloff for the second straight day, while cautious Fed minutes and looming Powell remarks at Jackson Hole added to investor uncertainty.

Boeing (NYSE: BA) has secured a $500 million agreement to supply Israel with two KC-46 Pegasus refueling aircraft, which will be financed entirely by U.S. military aid.

The deal, awaiting formal approval from Israel’s procurement committee, adds to the four KC-46s already in its fleet.

The order underscores Boeing’s ability to rely on defense contracts while its commercial aircraft division works through production delays and certification hurdles.

Investors watching the stock have often viewed defense as the stabilizer in Boeing’s portfolio, and a U.S.-funded foreign military sale reinforces that perception.

With taxpayer-backed financing, revenue visibility improves and cash flow risks shrink compared to cyclical jet demand.

For market participants, the broader implication is positioning. Lockheed Martin and Northrop Grumman have both benefited from Middle East contracts, but Boeing’s KC-46 is the only large-scale tanker program currently fielded with allies.

That creates a unique moat at a time when geopolitical tensions are elevating defense budgets worldwide.

This deal strengthens Boeing’s defense backlog and signals that U.S.-Israel cooperation will continue to flow through its order book.

For equity holders, it’s another indicator that the company’s defense arm can absorb shocks as management works to restore credibility in the commercial aviation sector.

Alphabet (NASDAQ: GOOGL) unveiled its Pixel 10 smartphone series, positioning the devices less as standalone hardware and more as gateways into its Gemini AI ecosystem.

The lineup, which includes the Pixel 10, Pixel 10 Pro, and a new foldable model, arrives weeks before Apple’s latest iPhone refresh.

For equity holders, the relevance is not the unit sales themselves.

Pixel’s market share remains in single digits, but the strategic role the phones play in funneling users toward Google’s subscription services is notable.

This positions Pixel as a test bed for Google’s most ambitious monetization strategy: leveraging AI to drive recurring revenue.

From a competitive standpoint, Apple’s delay of its Siri overhaul until 2026 gives Google room to brand itself as the AI-first device maker.

Samsung continues to grow its foldable segment, but it lacks a comparable subscription tie-in. Investors should view Pixel not as a hardware play, but as a lever to expand Google’s software margins and establish customer lock-in across Android.

The Pixel 10 launch reinforces Alphabet’s strategy of embedding AI services into daily consumer habits, shaping how its revenue mix evolves beyond advertising.

For investors, the key interest lies in whether bundled AI subscriptions can mature into a recurring revenue stream with margins rivaling cloud and ad sales, potentially redefining how Alphabet’s long-term growth is valued.

The market’s biggest winners rarely stay under the radar for long — but right now, we’ve found 7 companies with the same explosive setup the original tech giants once had.

They’re global, growing, and full of upside potential — but still overlooked by the average investor.

Our team has assembled a brand-new free report: “These 7 Stocks Will Be Magnificent in 2025.”

You’ll get all 7 names, backed by strong fundamentals, rising cash flow, and expanding market share — for free.

If you missed the rise of Amazon, Tesla, or Apple… don’t miss this.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

Some stocks merely survive uncertain markets… but a select few are built to shine.

Our newest free report reveals 7 companies with the strength and strategy to do exactly that.

Inside, you’ll uncover businesses with:

• Revenue growth fueled by powerful industry tailwinds
• Models built to withstand economic turbulence
• The potential to outperform traditional market benchmarks

This isn’t about chasing hype — it’s about finding resilience and upside where others miss it.

Don’t wait until the window closes.

While much of the market’s attention is on technology, the deliberate performance of CSX (NASDAQ: CSX) tells a more powerful story.

The company's climb toward a new all-time high is not a product of luck; it is a direct result of a powerful strategic shift and unwavering financial discipline.

Though the latest quarterly report showed a minor revenue miss, the underlying strength of the business is undeniable.

The company's EPS beat and robust cash flow of $635 million point to outstanding operational efficiency.

This financial strength is the core of its long-term strategy, enabling CSX to grow its dividend for 21 consecutive years and make key investments in its infrastructure.

The most compelling aspect of the investment case lies in its position within a consolidating industry.

With competitor Union Pacific's acquisition of Norfolk Southern, CSX is not a passive observer but an active participant, with reports suggesting it is exploring its merger options.

This dynamic positions CSX for future expansion and increased market share, providing a clear and compelling catalyst to push its stock past its prior record.

Wall Street’s conviction is evident, with a strong "Buy" consensus and a low short interest of just 1.35%.

The current momentum is more than a trend; it's a validation of a powerful, long-term investment thesis.

👉 Click here to get our closing report to your cell for free!

Shineco Inc [SISI] $6.70 (+32.94%)

Shineco jumped after announcing a blockchain partnership to tokenize stem cell assets, marking one of the first such applications in biotech.

Guess? Inc [GES] $16.83 (+26.12%)

Guess? rallied after agreeing to a $1.4 billion take-private deal with Authentic Brands Group at a 73% premium.

LanzaTech Global Inc [LNZA] $23.28 (+18.05%)

LanzaTech climbed after reporting quarterly results in line with expectations while highlighting cost-cutting initiatives, new SAF projects, and a £6.4M UK grant to advance commercial aviation fuel facilities.

James Hardie Industries Se [JHX] $18.64 (-34.44%)

James Hardie plunged after reporting weak fiscal Q1 earnings and warning that the U.S. housing slump is hitting demand for repairs and new construction.

Celldex Therapeutics [CLDX] $20.89 (-13.03%)

Celldex sank after halting development of barzolvolimab for eosinophilic esophagitis, raising pipeline concerns and Nasdaq delisting risks.

La-Z-Boy Inc [LZB] $34.41 (-12.02%)

La-Z-Boy tumbled after missing Q2 earnings estimates, issuing weak guidance, and reporting shrinking profit margins.

There’s a reason why Palantir only partners with serious operators.

Their software is used by the U.S. military, intelligence agencies, and Fortune 500s.

So when they announce a strategic collaboration in the autonomous robotics space, it’s worth watching closely.

Their newest partner?

A company with more than 4 million hours of autonomous fieldwork.

Real deployments. Real data. Real revenue.

This means faster incident detection.  Smarter machine learning.

And the kind of predictive security that could transform cities, campuses, and corporations.

This isn’t a beta test.  This is live and expanding.

And while the market sleeps, early investors may have a limited window to act.

Don’t wait for the headlines.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.